Clinical Trials Browser

Terminated × Bevacizumab × Genitourinary × Clear all

NCT03024437 2025-03-20

Atezolizumab in Combination With Entinostat and Bevacizumab in Patients With Advanced Renal Cell Carcinoma

Phase 1/2 Terminated

31 enrolled 19 charts

Kidney Neoplasms, Neoplasm Metastasis

NCT03272217 2025-01-07

Atezolizumab With Bevacizumab in Previously Untreated Metastatic/Unresectable Urothelial Cancer

Phase 2 Terminated

16 enrolled 12 charts

Carcinoma, Transitional Cell

NCT06448364 2024-11-06

LTbR

Phase 1 Terminated

DermatologicGastrointestinalGenitourinaryThoracic

Non-Muscle Invasive Bladder Neoplasms, Carcinoma, Non-Small-Cell Lung, Melanoma, Neoplasm Metastasis, Colorectal Neoplasms

NCT03878524 2024-03-04

Serial Measurements of Molecular and Architectural Responses to Therapy (SMMART) PRIME Trial

Phase 1 Terminated

BreastClassical hematologyGastrointestinalGenitourinaryLymphoidMyeloidOther hematologic neoplasmPlasma cell

Anemia, Blast Crisis, Breast Neoplasms, Hodgkin Disease, Lymphoma, Non-Hodgkin, Multiple Myeloma, Myelodysplastic Syndromes, Myeloproliferative Disorders, Neoplasm Metastasis, Pancreatic Neoplasms, Prostatic Neoplasms, Thrombocytosis, Leukemia, Lymphocytic, Chronic, B-Cell, Leukemia, Myelogenous, Chronic, BCR-ABL Positive, Leukemia, Myeloid, Accelerated Phase, Leukemia, Myeloid, Chronic-Phase, Leukemia, Myeloid, Acute, Leukemia, Myelomonocytic, Chronic, Hematologic Neoplasms, Precursor Cell Lymphoblastic Leukemia-Lymphoma, Myelodysplastic-Myeloproliferative Diseases, Leukemia, Myeloid, Chronic, Atypical, BCR-ABL Negative, Primary Myelofibrosis

NCT01198158 2019-03-06

Everolimus With or Without Bevacizumab in Treating Patients With Advanced Kidney Cancer That Progressed After First-Line Therapy

Phase 3 Terminated

77 enrolled 11 charts

Carcinoma, Renal Cell

NCT00934440 2017-06-14

5-AZ

Phase 1/2 Terminated

11 enrolled 10 charts

Carcinoma, Renal Cell, Kidney Neoplasms

NCT00651482 2017-04-11

Treatment of Refractory Metastatic Renal Cell Carcinoma With Bevacizumab and RAD001 (Everolimus)

Phase 2 Terminated

10 enrolled 14 charts

Carcinoma, Renal Cell, Kidney Neoplasms

NCT01264341 2017-02-14

Efficacy and Safety of Bevacizumab/Temsirolimus Combination to Treat Advanced Renal Cell Carcinoma

Phase 2 Terminated

Kidney Neoplasms

NCT00440973 2016-03-17

Safety Study of Specific Tumor Target Drug Plus Immune System Therapy in Patients With Kidney Cancer

Phase 2 Terminated

Carcinoma, Renal Cell, Kidney Neoplasms

NCT00913913 2015-12-01

Bevacizumab, Autologous Tumor/DC Vaccine, IL-2 and IFNα-2b in Metastatic Renal Cell Carcinoma (RCC) Patients

Phase 2 Terminated

8 enrolled 10 charts

Carcinoma, Renal Cell

NCT00601926 2015-06-15

Bevacizumab in Treating Patients With Unresectable or Metastatic Kidney Cancer

Phase 2 Terminated

5 enrolled 10 charts

Carcinoma, Renal Cell, Kidney Neoplasms

NCT00684996 2014-05-15

Bevacizumab With or Without MEDI-522 in Treating Patients With Unresectable or Metastatic Kidney Cancer

Phase 1/2 Terminated

5 enrolled 7 charts

Carcinoma, Renal Cell

NCT00523640 2014-02-11

A Phase II Trial of Gemcitabine, Capecitabine, and Bevacizumab in Metastatic Renal Cell Carcinoma

Phase 2 Terminated

30 enrolled 18 charts

Carcinoma, Renal Cell, Neoplasm Metastasis, Neoplasms

NCT00491738 2009-04-10

A Study Evaluating the Efficacy and Safety of Sunitinib With or Without Bevacizumab in First-Line Patients With Metastatic Renal Cell Cancer (SABRE-R)

Phase 2 Terminated

16 enrolled 5 charts

Carcinoma, Renal Cell